A Phase II, Open Label Study to Evaluate Denosumab in Patients With ER and/or PR-Positive, HER2-Negative Metastatic Breast Cancer (MBC) With Bone Metastases and Detectable Circulating Tumor Cells (CTCs)
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Denosumab (Primary)
- Indications Advanced breast cancer; Bone metastases; Male breast cancer
- Focus Therapeutic Use
- 22 Oct 2018 Status changed from recruiting to discontinued due to low accrual.
- 23 Mar 2017 Status changed from not yet recruiting to recruiting.
- 07 Mar 2017 New trial record